Immuneering Corporation (NASDAQ:IMRX) Insider Purchases $20,020.50 in Stock

Immuneering Corporation (NASDAQ:IMRX) insider Brett Matthew Hall purchased 7,415 shares of Immuneering stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average cost of $2.70 per share, with a total value of $20,020.50. Following the transaction, the insider now directly owns 353,311 shares of the company’s stock, valued at $953,939.70. This represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Brett Matthew Hall also recently made the following trade(s):

• On Monday, June 23rd, Brett Matthew Hall bought 6,007 shares of Immuneering stock. The shares were acquired at an average price of $2.43 per share, for a total transaction of $14,597.01.

Immuneering Price Performance

IMRX stock opened at $3.19 on Friday. Immuneering Corporation has a 1 year low of $1.00 and a 1 year high of $3.83. The company has a market cap of $114.81 million, a P/E ratio of -1.63 and a beta of 0.01. The stock’s fifty day moving average price is $1.75 and its 200-day moving average price is $1.77.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). As a group, analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price target on shares of Immuneering in a report on Wednesday, June 18th. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of Immuneering in a research note on Wednesday, June 18th. Oppenheimer dropped their price target on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Finally, Mizuho boosted their price objective on shares of Immuneering from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently made changes to their positions in the business. Tang Capital Management LLC bought a new stake in Immuneering during the fourth quarter valued at approximately $27,000. Jane Street Group LLC bought a new position in Immuneering in the first quarter worth approximately $32,000. Marshall Wace LLP purchased a new position in shares of Immuneering during the 4th quarter worth $47,000. First Manhattan CO. LLC. bought a new stake in shares of Immuneering during the 4th quarter valued at $71,000. Finally, XTX Topco Ltd increased its stake in shares of Immuneering by 177.2% in the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after purchasing an additional 20,871 shares in the last quarter. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.